2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149489
    JH-131e-153 742104-91-2 98%
    JH-131e-153, a diacylglycerol (DAG)-lactone, is a small molecule activator of Munc13-1, targeting the C1 domain. The activation sequence of JH-131e-153 on Munc13-1 is WT>I590≈R592A≈W588A. The C1 domain of Munc13-1 and protein kinase C (PKC) are homologous in sequence and structure. The activation sequence of JH-131e-153 on Munc13-1 and PKC was PKCα>Munc13-1>PKCε. JH-131e-153 regulates neuronal processes through Munc13-1 and can be further used in the study of neurodegenerative diseases.
    JH-131e-153
  • HY-149490
    AJH-836 388621-67-8 98%
    AJH-836 is an activator of Munc13-1 and PKC ε/α (Kd: 4.5 nM for PKCα) . AJH-836 triggers the translocation of Munc13-1 from the cytoplasm to the plasma membrane. AJH-836 can be used for research of neurodegenerative diseases.
    AJH-836
  • HY-149498
    Carbonic anhydrase inhibitor 15 98%
    Carbonic anhydrase inhibitor 15 (Compound 8) is a carbonic anhydrase inhibitor (Ki: 8.5 nM for hCA II). Carbonic anhydrase inhibitor 15 has analgesic effect.
    Carbonic anhydrase inhibitor 15
  • HY-149509
    α-Synuclein inhibitor 9 1510825-03-2 98%
    α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research..
    α-Synuclein inhibitor 9
  • HY-149527
    MAO-B-IN-23 2107978-22-1 98%
    MAO-B-IN-23 (Compound 11f) is a reversible and competitive MAO-B inhibitor (IC50: 1.44 μM, Ki: 0.51 μM).
    MAO-B-IN-23
  • HY-149536
    TWIK-1/TREK-1-IN-1 1440532-30-8 98%
    TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects.
    TWIK-1/TREK-1-IN-1
  • HY-149537
    TWIK-1/TREK-1-IN-2 1440532-32-0 98%
    TWIK-1/TREK-1-IN-2 (Compound 2g) is a TWIK-1/TREK-1 inhibitor. TWIK-1/TREK-1-IN-2 inhibits TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 10.13 μM and 15.5 μM. TWIK-1/TREK-1-IN-2 is an antidepressant.
    TWIK-1/TREK-1-IN-2
  • HY-149538
    TWIK-1/TREK-1-IN-3 1440532-33-1 99.61%
    TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects.
    TWIK-1/TREK-1-IN-3
  • HY-149542
    GSK-3β inhibitor 15 98%
    GSK-3β inhibitor 15 (Compound 54) is a GSK-3β inhibitor (IC50: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD).
    GSK-3β inhibitor 15
  • HY-149548
    2,3-Dinor-8-iso prostaglandin F1α 221664-04-6 98%
    2,3-Dinor-8-iso prostaglandin F1α is an isoprostanoid that can be used as a biomarker to assess psychological stress.
    2,3-Dinor-8-iso prostaglandin F1α
  • HY-149582
    Aβ-IN-7 98%
    Aβ-IN-7 (compound 5a) is a potent inhibitor of the Aβ aggregation. Aβ-IN-7 with 50 μM stabilize Aβ monomers in the small oligomeric species and prolong the nucleation process. Aβ-IN-7 inhibits Aβ fibril formation better than Aβ-IN-8 (HY-149583) in 50 μM.
    Aβ-IN-7
  • HY-149583
    Aβ-IN-8 98%
    Aβ-IN-8 (compound 7e) is a potent inhibitor of the Aβ aggregation.
    Aβ-IN-8
  • HY-149608
    Nurr1 agonist 5 3033875-32-7 98%
    Nurr1 agonist 5 (compound 5o) is a neuroprotective transcription factor Nurr1 agonist with a Kd of 0.5 μM and an EC50 of 3 μM.
    Nurr1 agonist 5
  • HY-149654
    FAAH/cPLA2α-IN-1 1696401-38-3 98%
    FAAH/cPLA2α-IN-1 is a dual inhibitor of FAAH and cPLA2α with IC50s of 32 and 47 nM, respectively.
    FAAH/cPLA2α-IN-1
  • HY-149702
    M1/M4 muscarinic agonist 1 98%
    M1/M4 muscarinic agonist 1 (compound 41) is a selective muscarinic M4/M1 agonist with EC50 values of 14 and 55 nM for M4 and M1, respectively. M1/M4 muscarinic agonist 1 can be used for research on mental diseases, such as schizophrenia, delusional disorder, etc.
    M1/M4 muscarinic agonist 1
  • HY-149704
    M1/M2/M4 muscarinic agonist 1 2640109-42-6 98%
    M1/M2/M4 muscarinic agonist 1 (Compound 42) is a muscarinic M4/M1/M2 agonist with EC50 values of 6.5, 26 and 210 nM for M4/M1/M2, respectively. M1/M2/M4 muscarinic agonist 1 can be used for research on mental diseases, such as schizophrenia, delusion, etc.
    M1/M2/M4 muscarinic agonist 1
  • HY-149725
    proMMP-9 selective inhibitor-1 98%
    proMMP-9 selective inhibitor-1 (compound 33) is a highly potent and selective inhibitor of proMMP-9 activation.
    proMMP-9 selective inhibitor-1
  • HY-149731
    M1/M2/M4 muscarinic agonist 2 98%
    M1/M2/M4 muscarinic agonist 2 (compound 43) is a muscarinic mAChR M1/M2/M4 agonist with EC50s of 30 nM, 200 nM and 6.2 nM, respectively.
    M1/M2/M4 muscarinic agonist 2
  • HY-149732
    M1/M4 muscarinic agonist 3 2640109-30-2 98%
    M1/M4 muscarinic agonist 3 (compound 44) is a muscarinic mAChR M1/M4 agonist with EC50s of 31 nM and 9.3 nM, respectively.
    M1/M4 muscarinic agonist 3
  • HY-149733
    M1/M2/M4 muscarinic agonist 3 2640109-28-8 98%
    M1/M2/M4 muscarinic agonist 3 (compound 45) is a muscarinic mAChR M1/M2/M4 agonist with EC50s of 3.2 nM, 32 nM and 1.7 nM, respectively.
    M1/M2/M4 muscarinic agonist 3
Cat. No. Product Name / Synonyms Application Reactivity